Entering text into the input field will update the search result below

Vertex's Symdeko nabs reimbursement in Australia

  • Vertex Pharmaceuticals (NASDAQ:VRTX) announces that reimbursement has been established in Australia for cystic fibrosis med Symdeko (tezacaftor/ivacaftor and ivacaftor) for patients at least 12 years old who are homozygous for the F508del mutation or who have one copy of the F505del mutation and another responsive residual function mutation in the CFTR gene.
  • The company says its cystic fibrosis medicines are reimbursed in 17 countries around the world.

Recommended For You

More Trending News

About VRTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VRTX--
Vertex Pharmaceuticals Incorporated